Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/- mice

Circulation Research

Volumn 93, Issue 5, 2003, Pages 464-471

  Bot, Ilze ^a,d   Von der Thüsen, Jan H ^a   Donners, Marjo M P C ^c   Lucas, Alexandra ^b   Fekkes, Madelon L ^a   De Jager, Saskia C A ^a   Kuiper, Johan ^e   Daemen, Mat J A P ^c   Van Berkel, Theo J C ^a   Heeneman, Sylvia ^c   Biessen, Erik A L ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e NONE

Author keywords

Atherosclerosis; Carotid arteries; Plaque stability; Serpin

Indexed keywords

ALPHA ACTIN; APOLIPOPROTEIN E; COLLAGEN; PLASMIN; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; VIRUS PROTEIN SERP1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MYXOMA VIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEINASE INHIBITION; STATISTICAL SIGNIFICANCE; VASCULAR SMOOTH MUSCLE;

ACTINS; ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; ARTERIOSCLEROSIS; CAROTID ARTERIES; CELL DIVISION; CELL LINE; CELLS, CULTURED; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; SERPINS; VIRAL PROTEINS;

EID: 0042416599     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000090993.01633.D4     Document Type: Article

References (36)

1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
2. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, Ploplis V, Muller M, Nagy A, Plow E, Gerard R, Edgington T, Risau W, Collen D. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N YAcad Sci. 1997;811:191-206.
3. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res. 2002;53:313-325.
4. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000;96:4212-4215.
5. Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis. 1997;132:131-138.
6. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol. 1999;36:949-955.
7. Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kuzuya F. Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis. 1990;83:9-14.
8. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells: a possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 1996;16:673-677.
9. Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Thrombin. Int J Biochem Cell Biol. 1998;30:641-646.
10. Kusch A, Gulba DC. Significance of the uPA/uPAR system for development of arteriosclerosis and restenosis. Z Kardiol. 2001;90:307-318.
11. Ye S, Goldsmith EJ. Serpins and other covalent protease inhibitors. Curr Opin Struct Biol. 2001;11:740-745.
12. Sjoland H, Eitzman DT, Gordon D, Westrick R, Nabel EG, Ginsburg D. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2000;20:846-852.
13. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:499-505.
14. DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation. 2001;104:1972-1977.
15. Ploplis VA, Castellino FJ. Attenuation of neointima formation following arterial injury in PAI-1 deficient mice. Ann N Y Acad Sci. 2001;936:466-468.
16. Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation. 2001;103:3105-3110.
17. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA, Castellino FJ. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol. 2001;158:107-117.
18. Upton C, Macen JL, Wishart DS, McFadden G. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology. 1990;179:618-631.
19. Upton C, Macen JL, Schreiber M, McFadden G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology. 1991;184:370-382.
20. Macen JL, Upton C, Nation N, McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology. 1993;195:348-363.
21. Nash P, Lucas A, McFadden G. SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. Adv Exp Med Biol. 1997;425:195-205.
22. Lomas DA, Evans DL, Upton C, McFadden G, Carrell RW. Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. J Biol Chem. 1993;268:516-521,
23. Nash P, Whitty A, Handwerker J, Macen J, McFadden G. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J Biol Chem. 1998;273:20982-20991.
24. Lucas A, Liu L, Macen J, Nash P, Dai E, Stewart M, Graham K, Etches W, Boshkov L, Nation PN, Humen D, Hobman ML, McFadden G. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation. 1996;94:2890-2900.
25. Hansen B, Boeke K, Berry GJ, Morris RE. Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. Transplantation. 2001;72:364-368.
26. Miller LW, Dai E, Nash P, Liu L, Icton C, Klironomos D, Fan L, Nation PN, Zhong R, McFadden G, Lucas A. Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation. 2000;101:1598-1605.
27. Lucas A, Dai EB, Liu LY, Guan HY, Nash P, McFadden G, Miller L. Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis. J Heart Lung Transplantation. 2000;19:1029-1038.
28. von der Thüsen JH, van Berkel TJC, Biessen EAL. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mica. Circulation. 2001;103:1164-1170.
29. Michon IN, Hauer AD, von der Thüsen JH, Molenaar TJM, van Berkel TJC, Biessen EAL, Kuiper J. Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro and in vivo. Biochim Biophys Acta. 2002;1591:87-97.
30. Babaev VR, Bobryshev YV, Stenina OV, Tararak EM, Gabbiani G. Heterogeneity of smooth muscle cells in atheromatous plaque of human aorta. Am J Pathol. 1990;136:1031-1042.
31. Kocher O, Gabbiani G. Cytoskeletal features of normal and atheromatous human arterial smooth muscle cells. Hum Pathol. 1986;17:875-880.
32. Bennett MR. Apoptosis in the cardiovascular system. Heart. 2002;87:480-487.
33. Van den Steen PE, Opdenakker G, Wormald MR, Dwek RA, Rudd PM. Matrix remodeling enzymes, the protease cascade and glycosylation. Biochim Biophys Acta. 2001;1528:61-73.
34. Falkenberg M, Tom C, DeYoung MB, Wen S, Linnemann R, Dichek DA. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci USA. 2002;99:10665-10670.
35. Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 1997;81:829-839.
36. Dai E, Guan H, Liu L, Little S, McFadden G, Vaziri S, Cao H, Ivanova JA, Bocksch L, Lucas A. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem. 2003;278:18563-18572.